Diagnostic and prognostic markers for human prostate cancer

The incidence and mortality of prostate cancer are increasing at alarming rates, partially due to an aging population. Early detection of prostate cancer, using clinically sensitive procedures and/or tumor markers (e.g., prostate‐specific antigen [PSA]), is of prime importance. However, the choice of therapeutic interventions for prostate cancer at the time of diagnosis is largely dependent on clinical and pathologic staging and prediction of the degree of aggressiveness of the disease. Clinically applicable prognostic markers are urgently needed to assist in the selection of optimal therapy.

[1]  A. Passaniti,et al.  Regulation of prostate‐specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix , 1994, The Prostate.

[2]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[3]  N. Block,et al.  Detection of prostatic‐inhibin‐like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line , 1994, The Prostate.

[4]  M. Takeichi,et al.  Cadherin cell adhesion receptors as a morphogenetic regulator. , 1991, Science.

[5]  J. Chin,et al.  Alternative splicing of PSP94 (prostatic secretory protein of 94 amino acids) mRNA in prostate tissue. , 1995, Oncogene.

[6]  R. Connelly,et al.  Effect of exogenous testosterone replacement on prostate‐specific antigen and prostate‐specific membrane antigen levels in hypogonadal men , 1995, Journal of surgical oncology.

[7]  M. Masai,et al.  Tumor marker doubling time in patients with prostate cancer: determination of prostate-specific antigen and prostatic acid phosphatase doubling time. , 1995, European urology.

[8]  F. Habib,et al.  Retinoblastoma and p53 genes as prognostic indicators in urological oncology. , 1994, Urologia internationalis.

[9]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[10]  W. Sause,et al.  The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). , 1992, International journal of radiation oncology, biology, physics.

[11]  G. Murphy,et al.  Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. , 1995, Anticancer research.

[12]  P. Carroll,et al.  Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression. , 1993, The Journal of urology.

[13]  W. Isaacs,et al.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. , 1992, Cancer research.

[14]  J. Schalken,et al.  Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differential hybridization analysis. , 1991, Cancer research.

[15]  S. Koide,et al.  Immunoglobulin binding factor of seminal plasma: a secretory product of human prostate. , 1992, Archives of andrology.

[16]  T. Sellers,et al.  Familial clustering of breast and prostate cancers and risk of postmenopausal breast cancer. , 1994, Journal of the National Cancer Institute.

[17]  E. Diamandis,et al.  Oral Contraceptive-induced Expression of Prostate-specific Antigen in the Female Breast (*) , 1995, The Journal of Biological Chemistry.

[18]  W. A. Soanes,et al.  THE DETECTION OF PROSTATIC ACID PHOSPHATASE BY ANTIBODY REACTIONS IN GEL DIFFUSION. , 1964, Journal of immunology.

[19]  D. Grignon,et al.  Localization of potential tumor suppressor loci to a < 2 Mb region on chromosome 17q in human prostate cancer. , 1995, Oncogene.

[20]  C. Logothetis,et al.  Secretion of prostate-specific antigen-suppressing activity by two human prostate carcinoma cell lines. , 1995, Urologic oncology.

[21]  M. Riggs,et al.  Stage at presentation and survival of white and black patients with prostate carcinoma , 1993, Cancer.

[22]  A. Rademaker,et al.  PR92 antigen in human prostate fluid: Elevated levels in prostate cancer , 1994, The Prostate.

[23]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[24]  W. Fair,et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.

[25]  K. Pummer,et al.  False positive prostate specific antigen values in the sera of women with renal cell carcinoma. , 1992, The Journal of urology.

[26]  H. Kanetake,et al.  Prostate specific antigen and prostatic acid phosphatase immunoreactivity as prognostic indicators of advanced prostatic carcinoma. , 1993, The Journal of urology.

[27]  M. Hussain,et al.  Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. , 1995, Cancer research.

[28]  T. Stamey,et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. , 1993, The Journal of clinical endocrinology and metabolism.

[29]  A. Whittemore,et al.  Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. , 1995, Journal of the National Cancer Institute.

[30]  T. Stamey,et al.  Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. , 1989, The Journal of urology.

[31]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .

[32]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[33]  K. Peters,et al.  Potential effects of age-specific reference ranges for serum prostate-specific antigen. , 1995, European urology.

[34]  W. Fair,et al.  Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. , 1995, Cancer research.

[35]  G. Murphy,et al.  Measurement of prostate‐specific membrane antigen in the serum with a new antibody , 1996, The Prostate.

[36]  A. Foti,et al.  Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. , 1977, The New England journal of medicine.

[37]  M. Benson,et al.  Molecular Stating of Prostate Cancer. II. A Comparison of the Application of an Enhanced Reverse Transcriptase Polymerase Chain Reaction Assay for Prostate Specific Antigen Versus Prostate Specific Membrane Antigen , 1995 .

[38]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[39]  R. Babaian,et al.  Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356. , 1994, The Journal of urology.

[40]  K. Honn,et al.  12‐Lipoxygenase, 12(S)‐HETE, and Cancer Metastasis a , 1994, Annals of the New York Academy of Sciences.

[41]  R. Vihko,et al.  Screening for carcinoma of the prostate rectal examination, and enzymatic and radioimmunologic measurements of serum acid phosphatase compared , 1985, Cancer.

[42]  J. Brooks,et al.  Molecular biology of prostate cancer. , 1994, Seminars in oncology.

[43]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[44]  H. Lilja.  A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[45]  P. Humphrey,et al.  Immunoreactive prostatic specific antigen in male periurethral glands. , 1992, The Journal of urology.

[46]  R. Thisted,et al.  Results of conservative management of clinically localized prostate cancer. , 1994, The New England journal of medicine.

[47]  C. Croce,et al.  Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. , 1994, Cancer research.

[48]  J. Srigley,et al.  Prostatic Tissue in Mature Cystic Teratomas of the Ovary , 1992, The American journal of surgical pathology.

[49]  K. Griffiths,et al.  Pathological and clinical associations of Ki‐67 defined growth fractions in human prostatic carcinoma , 1992, The Prostate.

[50]  T. Stamey,et al.  Serum prostate-specific antigen and the biologic progression of prostate cancer. , 1995, Urology.

[51]  R. deVere White,et al.  p53 mutations in benign prostatic hyperplasia. , 1993, Journal of the National Cancer Institute.

[52]  D. Grignon,et al.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. , 1995, Oncogene.

[53]  M. Garnick,et al.  Prostate Cancer: Screening, Diagnosis, and Management , 1993, Annals of Internal Medicine.

[54]  D. Robinson,et al.  Molecular characterization of the epitope in prostate and breast tumor-associated PR92 antigen. , 1989, Cancer research.

[55]  N. Konishi,et al.  p53 Mutations Occur in Clinical, but Not Latent, Human Prostate Carcinoma , 1995, Japanese journal of cancer research : Gann.

[56]  A Chiarodo,et al.  National Cancer Institute roundtable on prostate cancer: future research directions. , 1991, Cancer research.

[57]  P. Guinan,et al.  An evaluation of prostate specific antigen in prostatic cancer. , 1987, The Journal of urology.

[58]  G. Murphy,et al.  Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP‐based enzyme‐linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement , 1995, The Prostate.

[59]  E. Diamandis,et al.  Prostate-specific antigen in milk of lactating women. , 1995, Clinical chemistry.

[60]  H. Danielsen,et al.  Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. , 1995, Cancer research.

[61]  E. Diamandis,et al.  Original Articles: Prostate Cancer: Measurement of Serum Prostate Specific Antigen Levels in Women and in Prostatectomized Men With an Ultrasensitive Immunoassay Technique , 1995 .

[62]  J. Krieken.  Prostate Marker Immunoreactivity in Salivary Gland Neoplasms: A Rare Pitfall in Immunohistochemistry , 1993 .

[63]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.

[64]  D. Grignon,et al.  High frequency of mutator phenotype in human prostatic adenocarcinoma. , 1994, Oncogene.

[65]  R. deVere White,et al.  p53 in prostate cancer: frequent expressed transition mutations. , 1994, Journal of the National Cancer Institute.

[66]  P. Riegman,et al.  Characterization of the prostate-specific antigen gene: a novel human kallikrein-like gene. , 1989, Biochemical and biophysical research communications.

[67]  D. Isenberg,et al.  Serum metalloproteinases and their inhibitors: markers for malignant potential. , 1994, British Journal of Cancer.

[68]  W. K. Lam,et al.  Immunohistochemistry of prostatic acid phosphatase , 1981, The Prostate.

[69]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[70]  Z. Su,et al.  Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[71]  R. Vessella,et al.  Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid , 1994, International journal of cancer.

[72]  J. Neoptolemos,et al.  Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. , 1994, British Journal of Cancer.

[73]  J. J. Edwards,et al.  Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer. , 1982, Clinical chemistry.

[74]  K. Danenberg,et al.  Tumor suppressor gene P53 mutations in human prostate cancer , 1995, The Prostate.

[75]  Y. Arai,et al.  Osteocalcin: Is it a useful marker of bone metastasis and response to treatment in advanced prostate cancer? , 1992, The Prostate.

[76]  D. Armbruster,et al.  Prostate-specific antigen: biochemistry, analytical methods, and clinical application. , 1993, Clinical chemistry.

[77]  T. Teni,et al.  Serum and urinary prostatic inhibin-like peptide in benign prostatic hyperplasia and carcinoma of prostate. , 1988, Cancer letters.

[78]  M. Amirkhosravi,et al.  Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. , 1994, British Journal of Cancer.

[79]  J. Wilson,et al.  The prognostic significance of histological grading and pathological staging in carcinoma of the prostate. , 1983, The Journal of urology.

[80]  D. Grignon,et al.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. , 1995, Urology.

[81]  E. Liu,et al.  p53 gene alterations in human prostate carcinoma. , 1993, The Journal of urology.

[82]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[83]  K. Watt,et al.  Human prostate-specific antigen: structural and functional similarity with serine proteases. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[84]  J. Oesterling,et al.  Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate. , 1987, The Journal of urology.

[85]  D. Robinson,et al.  Monoclonal antibody PR92 with restricted specificity for tumor-associated antigen of prostate and breast carcinoma. , 1988, Cancer research.

[86]  O. Nilsson,et al.  Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. , 1993, The Journal of urology.

[87]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen. , 1992, The Journal of urology.

[88]  T. Y. Wang,et al.  Preliminary evaluation of measurement of serum prostate-specific antigen level in detection of prostate cancer. , 1986, Annals of clinical and laboratory science.

[89]  G. Blackledge,et al.  Role of prostate‐specific antigen as a predictor of outcome in prostate cancer , 1994, The Prostate. Supplement.

[90]  P. Schellhammer,et al.  Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas. , 1991, Cancer research.

[91]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[92]  P. Scardino,et al.  Elevated plasma chromogranin-A concentrations in prostatic carcinoma. , 1991, The Journal of urology.

[93]  James T. Wu.  Assay for prostate specific antigen (PSA): Problems and possible solutions , 1994, Journal of clinical laboratory analysis.

[94]  S. Mundle,et al.  Suppression of DNA synthesis and induction of apoptosis in rat prostrate by human seminal plasma inhibin (HSPI). , 1993, Cell biology international.

[95]  A. Varki,et al.  Selectin ligands. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[96]  R. Kuciel,et al.  Human prostatic acid phosphatase: selected properties and practical applications. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[97]  D. Tindall,et al.  Tumor-promoting phorbol ester down-regulates the androgen induction of prostate-specific antigen in a human prostatic adenocarcinoma cell line. , 1992, Cancer research.

[98]  J. Oesterling,et al.  Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging. , 1995, Seminars in surgical oncology.

[99]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[100]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[101]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[102]  H. G. van der Poel,et al.  Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. , 1993, Cancer research.

[103]  D. Grignon,et al.  Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. , 1995, Cancer research.

[104]  W. Isaacs,et al.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. , 1991, Cancer research.

[105]  S. Futaki,et al.  Immunoglobulin binding factor: A new tumor marker for prostatic tumors , 1994, The Prostate.

[106]  Y. Tsutsumi,et al.  Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. , 1990, Human pathology.

[107]  R. Fleischmann,et al.  Mutations of two P/WS homologues in hereditary nonpolyposis colon cancer , 1994, Nature.

[108]  E. Liu,et al.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma. , 1992, The Journal of urology.

[109]  T. Uchida,et al.  Microsatellite instability in prostate cancer. , 1995, Oncogene.

[110]  M. Barry,et al.  Patient-re ported complications and follow-up treatment after radical prostatectomy , 1993 .

[111]  M. Brawer.  Prostate-specific antigen: Critical issues , 1994 .

[112]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[113]  N. Block,et al.  Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor. , 1993, Cancer research.

[114]  K. Griffiths,et al.  Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters , 1992, The Prostate.

[115]  R. Cohen,et al.  Prostatic carcinoma: histological and immunohistological factors affecting prognosis. , 1990, British journal of urology.

[116]  J. Coventry,et al.  Relative performance characteristics of prostate specific antigen and prostatic specific antigen density for the diagnosis of carcinoma of the prostate. , 1995, Urologic oncology.

[117]  Y. Rochon,et al.  Western blot assay for prostate‐specific membrane antigen in serum of prostate cancer patients , 1994, The Prostate.

[118]  Masatoshi Watanabe,et al.  p53 Gene Mutations in Human Prostate Cancers in Japan: Different Mutation Spectra between Japan and Western Countries , 1994, Japanese journal of cancer research : Gann.

[119]  J. Brozna.  Cellular regulation of tissue factor , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[120]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[121]  R. Schäfer,et al.  P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. , 1994, Anticancer research.

[122]  D. Grignon,et al.  Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP). , 1994, Cancer letters.

[123]  D. Tindall,et al.  Hormonal regulation of prostate‐specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP , 1992, The Prostate.

[124]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[125]  D. Gillatt,et al.  What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker. , 1995, British journal of urology.

[126]  D. Chan,et al.  The value of serum enzymatic acid phosphatase in the staging of localized prostate cancer. , 1992, The Journal of urology.

[127]  T. Tammela,et al.  Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. , 1995, British Journal of Cancer.

[128]  C. Roehrborn,et al.  False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney. , 1995, Urology.

[129]  D. Grignon,et al.  Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. , 1993, Cancer research.

[130]  P. Carroll,et al.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki‐67 and PCNA expression , 1995, The Prostate.

[131]  R. Sadasivan,et al.  Mutant p53 expression in prostate carcinoma , 1993, The Prostate.

[132]  G. Pelletier,et al.  Immunohistgchemical Localization of a Prostatic Secretory Protein of 94 Amino Acids in Normal Prostatic Tissue, in Primary Prostatic Tumors and in Their Metastases , 1987 .

[133]  L. Jacobs,et al.  Fatty acid synthesis: a potential selective target for antineoplastic therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[134]  E. Diamandis,et al.  Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. , 1994, Clinical biochemistry.

[135]  D. Poller.  Prostate marker immunoreactivity in salivary gland neoplasms. , 1994, The American journal of surgical pathology.

[136]  P. Vihko,et al.  Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. , 1992, Endocrinology.

[137]  S. Koide,et al.  Identification of IgG and Fc-binding proteins in human seminal plasma and sperm. , 1991, Archives of andrology.

[138]  P. Schellhammer,et al.  A novel prostate carcinoma‐associated glycoprotein complex (PAC) recognized by monoclonal antibody turp‐27 , 1991, International journal of cancer.

[139]  E. Sproul,et al.  Significance of Increased Phosphatase Activity of Bone at the Site of Osteoplastic Metastases Secondary to Carcinoma of the Prostate Gland , 1936 .

[140]  A W Partin,et al.  OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. , 1995, Urology.

[141]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[142]  J. Risteli,et al.  Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. , 1993, Clinical chemistry.

[143]  J E Oesterling,et al.  PSA and staging of localized prostate cancer. , 1993, The Urologic clinics of North America.

[144]  R. Witherow,et al.  Urinary tissue factor levels in prostatic carcinoma: a potential marker of metastatic spread? , 1993, British journal of urology.

[145]  Y. Hannun,et al.  12(S)-HETE enhancement of prostate tumor cell invasion: selective role of PKC alpha. , 1994, Journal of the National Cancer Institute.

[146]  C. Croce,et al.  Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.

[147]  S. Hirohashi,et al.  E-cadherin gene mutations in human gastric carcinoma cell lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[148]  M. Ghoneim,et al.  Further experience with the urethral Kock pouch. , 1992, The Journal of urology.

[149]  A. Deblasio,et al.  Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.

[150]  George L. Wright,et al.  Generation and characterization of monoclonal antibodies to prostate secretory protein , 1990, International journal of cancer.

[151]  T. Deguchi,et al.  Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. , 1993, Cancer research.

[152]  M. Papotti,et al.  Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors. , 1989, Basic and applied histochemistry.

[153]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[154]  T. Stamey,et al.  An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands. , 1993, The Journal of urology.

[155]  L. Meijer,et al.  High-mobility-group proteins P1, I and Y as substrates of the M-phase-specific p34cdc2/cyclincdc13 kinase. , 1991, European journal of biochemistry.

[156]  J. Horm,et al.  Socioeconomic factors and cancer incidence among blacks and whites. , 1991, Journal of the National Cancer Institute.

[157]  W. Fraser Symmans,et al.  Comparative studies of prostate cancers among United States, Chinese, and Japanese patients: characterization of histopathology, tumor angiogenesis, neuroendocrine factors, and p53 protein accumulations. , 1995, Urologic oncology.

[158]  S. Li,et al.  Structure of human prostatic acid phosphatase gene. , 1992, Biochemical and biophysical research communications.

[159]  L. Deaven,et al.  Human prostatic acid phosphatase: cDNA cloning, gene mapping and protein sequence homology with lysosomal acid phosphatase. , 1989, Biochemical and biophysical research communications.

[160]  A. Pantuck,et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. , 1992, The Journal of urology.

[161]  T H Beaty,et al.  Risk of cancer in relatives of prostate cancer probands. , 1995, Journal of the National Cancer Institute.

[162]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[163]  T. Irimura,et al.  Colorectal cancer metastasis determined by carbohydrate-mediated cell adhesion: role of sialyl-LeX antigens. , 1993, Seminars in cancer biology.

[164]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[165]  W. Isaacs,et al.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.

[166]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[167]  J. Schalken,et al.  Decreased expression of E-cadherin in the progression of rat prostatic cancer. , 1992, Cancer research.

[168]  P. Kantoff,et al.  Detection of circulating tumor cells in men with localized prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  J. Mohler,et al.  Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. , 1994, The Journal of urology.

[170]  M. Benson,et al.  Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. , 1994, Urology.